Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 8Head & Neck 4Gynecologic 3Gastrointestinal 3CNS 3Thoracic 2Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Myeloid 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Carcinoma, Endometrioid 1

Interventions

Paclitaxel 108Carboplatin 97pembrolizumab 64Cisplatin 63Cyclophosphamide 45Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 25olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × adavosertib × Gynecologic × Clear all
NCT03345784 2024-02-20

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

National Cancer Institute (NCI)

Phase 1 Terminated
10 enrolled 15 charts
Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms, Carcinoma, Endometrioid

NCT02482311 2023-07-03

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
92 enrolled
BreastGynecologicThoracic

Ovarian Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02610075 2023-07-03

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

AstraZeneca

Phase 1 Completed
62 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡